Cannabidiol in medical marijuana: Research vistas and potential opportunities

Pharmacological Research

Volumn 121, Issue , 2017, Pages 213-218

  Rong, Carola ^a,c   Lee, Yena ^a,b   Carmona, Nicole E ^a   Cha, Danielle S ^a   Ragguett, Renee Marie ^a   Rosenblat, Joshua D ^a   Mansur, Rodrigo B ^a   Ho, Roger C ^e   McIntyre, Roger S ^a,b,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c American University of Integrative Sciences   (Netherlands)

^d UNIVERSITY OF TORONTO   (Canada)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anxiety; Cannabidiol; Cannabis; Cognition; Medical marijuana; Mood; Sleep

Indexed keywords

CANNABIDIOL; MEDICAL CANNABIS; DRONABINOL;

ANXIETY DISORDER; BEHAVIOR; BRAIN FUNCTION; COGNITIVE DEFECT; DEPRESSION; DRUG ACTIVITY; EMOTION; HUMAN; META ANALYSIS; MOOD DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SLEEP DISORDER; SYSTEMATIC REVIEW; AFFECT; ANXIETY; BRAIN; COGNITION; DRUG EFFECTS; INSOMNIA; SLEEP;

AFFECT; ANXIETY; BRAIN; CANNABIDIOL; COGNITION; DEPRESSION; DRONABINOL; HUMANS; MEDICAL MARIJUANA; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 85019566258     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.05.005     Document Type: Review

References (45)

1. Burns, L., World drug report 2013 by united nations office on drugs and crime new York: PB − united nations, 2013ISBN: 978-92-1-056168-6, 151 pp. grey literature. Drug Alcohol Rev., 33(March (2)), 2014, 216.
2. Degenhardt, L., Ferrari, A.J., Calabria, B., Hall, W.D., Norman, R.E., McGrath, J., et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One, 10(October (8)), 2013, e76635.
3. Dahlgren, M.K., Sagar, K.A., Racine, M.T., Dreman, M.W., Gruber, S.A., Marijuana use predicts cognitive performance on tasks of executive function. J. Stud. Alcohol Drugs 77:March (2) (2016), 298–308.
4. Whiting, P.F., Wolff, R.F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A.V., et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313:24 (2015), 2456–2473.
5. Murray, R.M., Quigley, H., Quattrone, D., Englund, A., Di Forti, M., Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry 15:October (3) (2016), 195–204.
6. Andrade, C., Cannabis and neuropsychiatry, 1: benefits and risks. J. Clin. Psychiatry 77:May (5) (2016), 4e551–e554.
7. Cabral, G.A., Rogers, T.J., Lichtman, A.H., Turning over a new leaf: cannabinoid and endocannabinoid modulation of immune function. J. Neuroimmune Pharmacol. 10:June (2) (2015), 193–203.
8. Micale, V., Di Marzo, V., Sulcova, A., Wotjak, C.T., Drago, F., Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol. Ther. 138:April (1) (2013), 18–37.
9. McPartland, J.M., Duncan, M., Di Marzo, V., Pertwee, R.G., Are cannabidiol and Δ(9) −tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br. J. Pharmacol. 172:Feburary (3) (2015), 737–753.
10. Hill, M.N., Patel, S., Campolongo, P., Tasker, J.G., Wotjak, C.T., Bains, J.S., Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J. Neurosci. 30:November (45) (2010), 14980–14986.
11. Serrano, A., Parsons, L.H., Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol. Ther. 132:December (3) (2011), 215–241.
12. Thomas, A., Baillie, G.L., Phillips, A.M., Razdan, R.K., Ross, R.A., Pertwee, R.G., Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 150:March (5) (2007 Mar), 613–623.
13. Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134:4 (2001), 845–852.
14. Morgan, C.J.A., Page, E., Schaefer, C., Chatten, K., Manocha, A., Gulati, S., et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br. J. Psychiatry 202:May (5) (2013), 381–382.
15. Russo, E.B., Burnett, A., Hall, B., Parker, K.K., Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30:August (8) (2005 Aug), 1037–1043.
16. Morgan, C.J.A., Das, R.K., Joye, A., Curran, H.V., Kamboj, S.K., Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict. Behav. 38:September (9) (2013), 2433–2436.
17. Englund, A., Morrison, P.D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J. Psychopharmacol. 27:January (1) (2013 Jan), 19–27.
18. Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:February (3) (2010), 764–774.
19. Nunberg, H., Kilmer, B., Pacula, R.L., Burgdorf, J., An analysis of applicants presenting to a medical marijuana specialty practice in california. J. Drug Policy Anal, 4(February (1)), 2011, 10.2202/1941-2851.1017 (Internet).
20. Bergamaschi, M.M., Queiroz, R.H.C., Chagas, M.H.N., de Oliveira, D.C.G., De Martinis, B.S., Kapczinski, F., et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36:February (6) (2011), 1219–1226.
21. Crippa, J.A.S., Derenusson, G.N., Ferrari, T.B., Wichert-Ana, L., Duran, F.L.S., Martin-Santos, R., et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 25:January (1) (2011), 121–130.
22. Das, R.K., Kamboj, S.K., Ramadas, M., Yogan, K., Gupta, V., Redman, E., et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology 226:April (4) (2013), 781–792.
23. Gunduz-Cinar, O., MacPherson, K.P., Cinar, R., Gamble-George, J., Sugden, K., Williams, B., et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 18:July (7) (2013), 813–823.
24. Kaplan, G.B., Moore, K.A., The use of cognitive enhancers in animal models of fear extinction. Pharmacol. Biochem. Behav. 99:August (2) (2011), 217–228.
25. McIntyre, R.S., Lee, Y., Cognition in major depressive disorder: a systemically important functional index (SIFI). Curr. Opin. Psychiatry 29:January (1) (2016), 48–55.
26. McIntyre, R.S., Soczynska, J.Z., Woldeyohannes, H.O., Alsuwaidan, M.T., Cha, D.S., Carvalho, A.F., et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr. Psychiatry 56:January (2015), 279–282.
27. McIntyre, R.S., Lee, Y., Mansur, R.B., Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr. 20:Suppl. 1 (2015), 20–30 (quiz 31 Dec).
28. Gruber, S.A., Sagar, K.A., Dahlgren, M.K., Racine, M.T., Smith, R.T., Lukas, S.E., Splendor in the grass? a pilot study assessing the impact of medical marijuana on executive function. Front. Pharmacol., 13(October (7)), 2016, 355.
29. Puri, B., Hall, A., Ho, R.C., (eds.) Revision Notes in Psychiatry, 3rd edn, 2014, CRC Press, New York.
30. 9-THC)-induced disruption in stop signal task performance. Exp. Clin. Psychopharmacol. 24:October (5) (2016), 320–330.
31. Morgan, C.J.A., Schafer, G., Freeman, T.P., Valerie Curran, H., Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br. J. Psychiatry 197:October (4) (2010), 285–290.
32. Metrik, J., Jackson, K., Bassett, S.S., Zvolensky, M.J., Seal, K., Borsari, B., The mediating roles of coping, sleep, and anxiety motives in cannabis use and problems among returning veterans with PTSD and MDD. Psychol. Addict. Behav. 30:November (7) (2016), 743–754.
33. Zhang, M.W., Ho, R.C., The cannabis dilemma: a review of its associated risk and clinical efficacy. J. Addict., 2015, 707596.
34. Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., et al. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology 103:April (2016), 16–26.
35. Gomes, F.V., Resstel, L.B.M., Guimarães, F.S., The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology 213:February (2–3) (2011), 465–473.
36. Hassan, S., Eldeeb, K., Millns, P.J., Bennett, A.J., Alexander, S.P.H., Kendall, D.A., Cannabidiol enhances microglial phagocytosis via transient receptor potential (TRP) channel activation. Br. J. Pharmacol. 171:May (9) (2014), 2426–2439.
37. Devinsky, O., Cilio, M.R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55:June (6) (2014), 791–802.
38. Zammit, G.K., Weiner, J., Damato, N., Sillup, G.P., McMillan, C.A., Quality of life in people with insomnia. Sleep 22:May Suppl. 2 (1999), S379–85.
39. Gates, P.J., Albertella, L., Copeland, J., The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med. Rev. 18:December (6) (2014), 477–487.
40. Chagas, M., Eckeli, A.L., Zuardi, A.W., Pena-Pereira, M.A., Sobreira-Neto, M.A., Sobreira, E.T., et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J. Clin. Pharm. Ther. 39:5 (2014), 564–566.
41. Nicholson, A.N., Turner, C., Stone, B.M., Robson, P.J., Effect of Δ-9-Tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J. Clin. Psychopharmacol., 24(June (3)), 2004, 305.
42. Pivik, R.T., Zarcone, V., Dement, W.C., Hollister, L.E., Delta-9-tetrahydrocannabinol and synhexl: effects on human sleep patterns. Clin. Pharmacol. Ther. 13:May (3) (1972), 426–435.
43. Chait, L.D., Zacny, J.P., Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psychopharmacology 107:2–3 (1992), 255–262.
44. Budney, A.J., Hughes, J.R., Moore, B.A., Vandrey, R., Review of the validity and significance of cannabis withdrawal syndrome. Am. J. Psychiatry 161:November (11) (2004), 1967–1977.
45. Fasinu, P.S., Phillips, S., ElSohly, M.A., Walker, L.A., Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy 36:July (7) (2016), 781–796.